Cancer research made in Tuebingen
iFIT Cluster of Excellence

Prof. Dr. Lars Zender
Medical Director of the Clinic for Medical Oncology and Pulmonology
iFIT Cluster of Excellence Spokesperson

Lars.Zender@med.uni-tuebingen.de

• Wolter, K., Zender, L. Therapy-induced senescence — an induced synthetic lethality in liver cancer?. Nat Rev Gastroenterol Hepatol 17, 135–136 (2020). https://doi.org/10.1038/s41575-020-0262-3
• Li, X., Ramadori, P., Pfister, D. et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 21, 541–557 (2021). https://doi.org/10.1038/s41568-021-00383-9
• Pfister, D., Núñez, N.G., Pinyol, R. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021). https://doi.org/10.1038/s41586-021-03362-0
• Reautschnig, P., Wahn, N., Wettengel, J. et al. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo. Nat Biotechnol 40, 759–768 (2022). https://doi.org/10.1038/s41587-021-01105-0
•  Schwabe, R., Affo, S., Nair, A. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 39, 866-882 (2021). https://doi.org/10.1016/j.ccell.2021.03.012
• Bresnahan E, Ramadori P, Heikenwalder M, Zender L, Lujambio A. Novel patient-derived preclinical models of liver cancer. J Hepatol. 2020 Feb;72(2):239-249. 10.1016/j.jhep.2019.09.028.
• Zender, L., Artista, L., Moschopoulou, A. et al. MYC determines lineage commitment in kras driven primary liver cancer development. J Hepatol. 2023 Mar 9;S0168-8278(23). 10.1016/j.jhep.2023.02.039
•  Rudalska, R., Harbig, J., Snaebjornsson, M.T. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2, 201–217 (2021). https://doi.org/10.1038/s43018-020-00168-3
• Brenner, E., Schörg, B.F., Ahmetlić, F. et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335 (2020). https://doi.org/10.1038/s41467-020-14987-6
• Hinterleitner, C., Strähle, J., Malenke, E. et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun 12, 7005 (2021). https://doi.org/10.1038/s41467-021-27303-7   

Prof. Dr. Bernd Pichler
Director of the Department of Preclinical Imaging and Radiopharmacy
iFIT Cluster of Excellence Spokesperson

Bernd.Pichler@med.uni-tuebingen.de

Learn more

Selection of iFIT-related publications with the highest impact factor.

• Feil S, Stowbur D, Schörg BF, Ehrlichmann W, Reischl G, Kneilling M, Pichler BJ, Feil R. Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice. Circ Res. 2023 Mar 17;132(6):747-750. 10.1161/CIRCRESAHA.122.322296.
• Rudalska, R., Harbig, J., Snaebjornsson, M.T. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat Cancer 2, 201–217 (2021). https://doi.org/10.1038/s43018-020-00168-3.
• Brenner, E., Schörg, B.F., Ahmetlić, F. et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 11, 1335 (2020). https://doi.org/10.1038/s41467-020-14987-6
• Nording, H., Baron, L., Haberthür, D. et al. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun 12, 3352 (2021). https://doi.org/10.1038/s41467-021-23499-w
• Zekri, L., Vogt, F., Jung, G. et al. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021, Feb 5;13(2):e11902. 10.15252/emmm.201911902.
• Montes-Mojarro, IA., Steinhilber, J., Griessinger, C.M. et al. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. Leukemia 36, 2050–2063 (2022). https://doi.org/10.1038/s41375-022-01617-x
• Marciano S, Ionescu TM, Saw RS, Cheong RY, Kirik D, Maurer A, Pichler BJ, Herfert K. Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2122552119. 10.1073/pnas.2122552119.
• Rammensee, HG., Wiesmüller, KH., Chandran, P.A. et al. A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. j. immunotherapy cancer 7, 307 (2019). https://doi.org/10.1186/s40425-019-0796-5.
• Hoffmann, S., Reck, D., Griessinger, C. et al. Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. Theranostics. 2019 Aug 12;9(20): 5869-5885. 10.7150/thno.33275.
• Schwenk, J., Schörg, B., Kneilling, M. et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo (18)F-FDG-PET. Theranostics. 2020 Jan 1;10(2):925-937. 10.7150/thno.35989 

Prof. Dr. Juliane Walz
iFIT Cluster of Excellence Spokesperson
Officer for Equal Opportunities

juliane.walz@med.uni-tuebingen.de

Learn more

Selection of iFIT-related publications with the highest impact factor.

• Nelde, A., Bilich, T., Heitmann, J.S. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol 22, 74–85 (2021). https://doi.org/10.1038/s41590-020-00808-x
• Becker, M., Strengert, M., Junker, D. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. Nat Commun 12, 1152 (2021). https://doi.org/10.1038/s41467-021-20973-3
• Heitmann, J.S., Bilich, T., Tandler, C. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617–622 (2022). https://doi.org/10.1038/s41586-021-04232-5
• Bauer, J., Köhler, N., Maringer, Y. et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 13, 6401 (2022). https://doi.org/10.1038/s41467-022-33746-3
• Heitmann, J.S., Tandler, C., Marconato, M. et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun 14, 5032 (2023). https://doi.org/10.1038/s41467-023-40758-0
• Goyal, A., Bauer, J., Hey, J. et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun 14, 6731 (2023). https://doi.org/10.1038/s41467-023-42417-w
• Hoenisch Gravel, N., Nelde, A., Bauer, J. et al. TOF_IMS mass spectrometry-based immunopeptidomics refines tumor antigen identification. Nat Commun 14, 7472 (2023). https://doi.org/10.1038/s41467-023-42692-7    

Dr. Ellen Brenner
iFIT Cluster of Excellence Managing Director

07071 29-86219

ellen.brenner@med.uni-tuebingen.de

Learn more